ReviewCurrent rheumatology reports2015
Biologic-associated infections in pediatric rheumatology.
Review in Current rheumatology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 52 citations in OpenAlex.
- Tuberculosis infection in BCG vaccinated children and adolescents with rheumatological diseases treated by tumor necrosis factor-α inhibitors.European journal of pediatrics · 2026Article
- Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections.European journal of pediatrics · 2024Review
- Risk of tuberculosis in children with rheumatologic diseases treated with biological agents: A cross-sectional cohort study.Archives of rheumatology · 2023Article
- Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening).European journal of pediatrics · 2022Review
- Are infections in children with juvenile idiopathic arthritis more frequent than in healthy children? A prospective multicenter observational study.Frontiers in pediatrics · 2022Article
- Vaccination completeness in children with rheumatic diseases: A longitudinal, observational multicenter cohort study in Switzerland.Frontiers in pediatrics · 2022Article
- Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.Rheumatology international · 2021Article
- Biologics in juvenile idiopathic arthritis-main advantages and major challenges: A narrative review.Archives of rheumatology · 2021Review
- [Travel vaccinations in rheumatic diseases : Specific considerations in children and adults].Zeitschrift fur Rheumatologie · 2020Review
- Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.Clinical microbiology reviews · 2020Review
- Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee.Arthritis research & therapy · 2020Observational
- Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.Clinical rheumatology · 2020Article
- The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study.Clinical rheumatology · 2019Article
- Article
- Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.Paediatric drugs · 2018Article
- Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis - single-centre experience.Reumatologia · 2018Article
- ATS Core Curriculum 2017: Part II. Pediatric Pulmonary Medicine.Annals of the American Thoracic Society · 2017Review
- Juvenile Idiopathic Arthritis.Balkan medical journal · 2017Article
- Anticytokine Autoantibodies: Association with Infection and Immune Dysregulation.Antibodies (Basel, Switzerland) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the past 15 years, biologics for juvenile idiopathic arthritis (JIA) therapy has led to new options. However, despite the high effectiveness and safety profile of these agents, infections are of great concern. The risk for bacterial infections, which appears to be increased in JIA patients as a result of the disease itself, seems to be increased further by antirheumatic treatment. Combining data from several sources, infection rates appear to be comparable for abatacept (1.33/100 person-years (PY); 95 % confidence interval (CI) = 0.50-2.48), adalimumab (1.42/100 PY; 1.01-1.99), and etanercept (1.28/100 PY; 1.06-1.55); higher with golimumab (3.03/100 PY; 1.26-7.29) and infliximab (3.42/100 PY; 1.71-6.84); and even higher with tocilizumab (8.62/100 PY; 6.69-11.10). The rate of serious infection was lowest with methotrexate (0.67/100 PY; 0.48-0.93). In patient cohorts treated with methotrexate without a biologic as a comparator, risk ratios for serious infections were significantly increased for all biologics, except abatacept, because of insignificant patient numbers. Opportunistic infections, including tuberculosis, were very rare. Herpes zoster was the only specific infection occurring frequently throughout the studies. Thus, the safety profiles of approved biologics are highly acceptable. Although this conclusion is based on limited experience and is not easily expanded to the interleukin (IL)-1 inhibitor canakinumab or the T cell activation inhibitor abatacept, both these agents have demonstrated an excellent safety profile so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.